character
antibodi
respons
tanzanian
volunt
live
malariaendem
region
immun
repeat
intraven
inject
irradi
pfspz
pfspz
vaccin
underw
chmi
live
homolog
parasit
fig
serum
igm
igg
antibodi
measur
flow
cytometri
live
pfspz
increas
follow
immun
show
clear
associ
protect
chmi
fig
c
supplementari
fig
b
memori
b
cell
five
protect
individu
immort
screen
stain
intact
pfspz
isol
human
monoclon
antibodi
surfac
antigen
pfspz
supplementari
fig
igg
monoclon
antibodi
bound
pfspz
high
affin
fig
e
interestingli
two
donor
pfspzspecif
igm
igg
monoclon
antibodi
isol
igm
antibodi
recov
much
higher
number
fig
igm
antibodi
fewer
still
substanti
mutat
compar
igg
antibodi
consist
origin
igm
memori
b
cell
fig
particular
find
antibodi
lineag
contain
igm
igg
member
suggest
incomplet
switch
respons
despit
repeat
immun
supplementari
fig
result
demonstr
immun
pfspz
vaccin
induc
robust
antibodi
respons
retain
signific
igm
compon
identifi
featur
effect
neutral
monoclon
antibodi
produc
protect
individu
test
panel
igg
antibodi
vitro
capac
inhibit
pfspz
travers
invas
human
hepatocyt
cell
line
fig
invasioninhibitori
activ
vari
among
antibodi
significantli
correl
bind
affin
pfspz
fig
subset
antibodi
test
vivo
mous
human
liver
model
capac
protect
natur
mosquito
bitetransmit
infect
pfspz
antibodi
potent
reduc
liver
burden
other
less
effect
fig
find
suggest
vivo
neutral
activ
may
relat
fine
specif
antibodi
next
set
identifi
target
antigen
monoclon
antibodi
strikingli
although
use
antigenagnost
approach
identifi
antibodi
bound
pfspz
surfac
regardless
specif
found
antibodi
bound
recombin
pfcsp
fig
e
confirm
immunogen
protein
pfspz
understand
basi
effect
neutral
map
specif
monoclon
antibodi
use
synthet
peptid
cover
nterminu
nanp
repeat
region
ntermin
junction
connect
region
ntermin
domain
nanp
repeat
cterminu
pfcsp
bind
classic
nanp
repeat
peptid
pfcsp
cterminu
recombin
pfcsp
pfspz
correl
efficaci
supplementari
fig
interestingli
howev
bind
minim
peptid
cover
junction
ntermin
domain
nanp
repeat
share
characterist
potent
vivo
neutral
antibodi
fig
potent
antibodi
also
recogn
peptid
suggest
capac
bind
nanp
repeat
ntermin
junction
pfcsp
main
featur
effici
neutral
anoth
distinct
characterist
potent
antibodi
common
usag
famili
allel
carri
tryptophan
arginin
posit
defin
includ
allel
share
ident
fig
supplementari
fig
supplementari
tabl
strikingli
common
vh
gene
use
igm
antibodi
isol
donor
g
u
almost
antibodi
carri
supplementari
fig
collect
data
indic
potent
antibodi
dual
specif
share
common
vh
gene
usag
importantli
antibodi
isol
four
five
donor
suggest
antibodi
belong
public
lineag
therefor
potenti
readili
induc
vaccin
investig
influenc
somat
mutat
bind
antibodi
pfcsp
focus
two
clonal
relat
highli
mutat
antibodi
fig
unmut
common
ancestor
uca
antibodi
carri
tryptophan
posit
abl
bind
pfcsp
pfspz
low
affin
substitut
serin
commonli
found
allel
result
loss
bind
fig
c
find
conjunct
high
frequenc
igm
sequenc
identif
put
allel
carri
germlin
sequenc
obtain
nonb
cell
donor
g
u
w
supplementari
fig
identifi
allel
carri
prefer
featur
initi
lineagespecif
antibodi
respons
pfcsp
branch
point
clone
achiev
sever
mutat
high
affin
bind
pfspz
pfcsp
mutat
increas
breadth
confer
uniqu
abil
bind
fig
supplementari
fig
despit
similar
bind
pfspz
pfcsp
substanti
potent
vivo
assay
fig
suggest
acquisit
bind
key
factor
potent
neutral
interestingli
mutagenesi
studi
suggest
remain
critic
residu
bind
becom
dispens
high
affin
bind
nanp
fulllength
pfcsp
fulli
mutat
antibodi
fig
contrast
second
clonal
famili
consist
full
bind
pfcsp
pfspz
alreadi
achiev
branch
point
remain
mutat
appear
redund
supplementari
fig
investig
origin
specif
germlin
antibodi
analys
bind
uca
variou
antibodi
pfcsp
peptid
use
sensit
beadbas
assay
uca
bound
suggest
antibodi
gener
start
nanpspecif
gain
affin
somat
mutat
supplementari
fig
data
delin
pathway
antibodi
develop
depend
specif
vh
allel
lead
antibodi
dual
specif
identifi
minim
residu
recogn
antibodi
pfcsp
ntermin
junction
perform
mutat
analysi
version
use
provid
longer
scaffold
bind
fig
loss
bind
certain
peptid
identifi
specif
motif
dpnanp
recogn
antibodi
regardless
vh
gene
usag
find
combin
data
peptid
array
experi
supplementari
fig
identifi
ntermin
junction
bind
site
potent
neutral
antibodi
includ
first
unit
nanp
repeat
region
flank
nonrepeat
sequenc
provid
molecular
basi
dual
specif
antibodi
gain
structur
insight
recognit
ntermin
junction
attempt
crystal
sever
antibodi
success
crystal
complex
peptid
fig
supplementari
tabl
ctermin
half
npdpnan
residu
peptid
visibl
contact
made
heavychain
residu
shown
fab
buri
surfac
area
fig
specif
heavychain
cdr
loop
form
groov
peptid
resid
fig
supplementari
fig
addit
three
interfaci
water
involv
extens
hydrogenbond
network
connect
side
chain
base
cdr
cdr
supplementari
fig
interact
fig
supplementari
fig
confirm
latter
residu
critic
bind
indic
mutagenesi
experi
peptid
residu
except
display
rel
larg
buri
surfac
area
fig
weak
electron
densiti
residu
visibl
peptid
termini
fig
supplementari
fig
indic
structur
flexibl
highlight
sequenc
dpn
princip
bind
motif
interestingli
dpn
sequenc
display
pseudo
turn
stabil
hydrogen
bond
aspart
side
chain
asparagin
backbon
amid
conform
similar
turn
observ
unbound
nanp
peptid
solut
crystal
structur
free
antibodybound
peptid
fig
isol
dpn
motif
also
present
ctermin
peptid
may
explain
bind
fig
notwithstand
signific
differ
dpn
flank
residu
ctermin
ntermin
junction
peptid
ndpnr
versu
pdpna
respect
bind
npdp
nanp
repeat
suggest
aspart
residu
dpn
motif
interchang
asparagin
bind
studi
peptid
mutant
valid
specif
toward
dpn
npn
motif
fig
central
dpn
npn
motif
within
peptid
mutat
dpa
aan
bind
complet
abrog
contrast
third
dpn
motif
present
cterminu
peptid
contribut
bind
possibl
indic
import
flank
residu
optim
bind
overal
data
impli
potenti
peptidebind
promiscu
allow
bind
divers
epitop
pfcsp
sinc
antibodi
bind
peptid
expect
less
promiscu
bind
slightli
larger
specif
sequenc
find
potent
monoclon
antibodi
recogn
defin
ntermin
junction
peptid
suggest
region
could
compon
effect
subunit
vaccin
initi
attempt
investig
whether
peptid
might
suffici
induc
protect
respons
immun
balbc
mice
conjug
klh
mice
produc
igg
antibodi
specif
peptid
best
weakli
reactiv
peptid
supplementari
fig
b
strikingli
spite
abil
bind
pfspz
mous
sera
unabl
inhibit
pfspz
invas
hepatocyt
cell
line
vitro
suggest
dual
specif
nanp
ntermin
junction
may
requir
potent
neutral
function
supplementari
fig
relianc
dualspecif
antibodi
isol
specif
human
allel
suggest
mice
counterpart
human
gene
may
suitabl
model
organ
test
novel
cspbase
vaccin
rather
organ
aotu
monkey
similar
vh
gene
repertoir
human
contain
gene
carri
equival
may
suitabl
choic
studi
show
antibodi
produc
vaccin
protect
african
individu
contain
highli
mutat
igg
compon
well
import
igm
compon
fewer
substanti
mutat
also
seen
respons
bloodstag
plasmodium
larg
igm
compon
would
consist
stimul
margin
zone
b
cell
spleen
follow
intraven
immun
particul
strikingli
igg
antibodi
identifi
recogn
pfcsp
consist
previou
studi
describ
immunodomin
protein
abund
pfspz
find
agreement
previou
work
separ
describ
import
pfcsp
nanp
repeat
region
importantli
highlight
fact
antibodi
target
epitop
region
simultan
potent
antibodi
exclus
recogn
individu
site
interestingli
structur
analysi
peptid
mutat
data
indic
antibodi
origin
specif
nanp
motif
acquir
complet
unrel
specif
rather
gain
promiscu
sequenc
centr
dpn
motif
dual
specif
larg
extent
encod
allel
also
requir
extens
somat
mutat
import
dual
specif
highlight
fact
immun
singl
peptid
suffici
confer
protect
despit
elicit
pfspzbind
antibodi
increas
potenc
dualspecif
antibodi
could
due
proxim
ntermin
junction
region
klkqp
pfcsp
involv
cleavag
nterminu
allow
pfspz
invas
ntermin
junction
region
includ
advanc
malaria
vaccin
candid
rt
may
explain
limit
efficaci
malariaendem
find
support
continu
work
develop
whole
pfspz
vaccin
contain
entir
pfcsp
provid
rational
attempt
develop
refin
vaccin
approach
elicit
dualspecif
antibodi
use
primeboost
strategi
improv
find
potent
antibodi
share
common
vh
gene
usag
multipl
donor
consist
public
antibodi
respons
readili
induc
vaccin
result
reminisc
previou
work
use
particular
vh
gene
allel
form
respons
stem
influenza
justifi
effort
investig
role
vh
gene
polymorph
protect
antibodi
respons
nevertheless
whether
antibodi
suffici
protect
human
individu
protect
remain
establish
possibl
reason
latter
includ
lack
allel
incomplet
matur
antibodi
insuffici
product
potent
antibodi
antibodi
describ
could
use
obtain
proof
concept
antibodi
alon
protect
vivo
human
previous
shown
mice
nonhuman
pave
way
use
antibodi
prophylaxi
p
falciparum
infect
develop
improv
antibodybas
subunit
malaria
vaccin
asept
purifi
cryopreserv
pfspz
strain
provid
use
serum
monoclon
antibodi
bind
experi
pfspz
produc
center
infecti
diseas
research
seattl
use
vitro
vivo
function
assay
follow
inform
consent
blood
sampl
use
studi
collect
malaria
preexpos
volunt
clinic
phase
clinic
trial
safeti
immunogen
protect
efficaci
pfspz
vaccin
bagamoyo
tanzania
trial
perform
accord
good
clinic
practic
protocol
approv
institut
review
board
ifakara
health
institut
ihiirb
ref
nation
institut
medic
research
tanzania
ethikkommiss
basel
eknz
basel
switzerland
refer
number
protocol
approv
tanzania
food
drug
author
tfda
ref
regist
clinic
trialsgov
conduct
us
fda
ind
detail
inform
studi
procedur
trial
given
jongo
et
al
manuscript
submit
briefli
healthi
male
volunt
age
year
random
direct
venou
inocul
dvi
dose
normal
salin
pfspz
pfspz
vaccin
vaccin
efficaci
assess
homolog
control
human
malaria
infect
chmi
dvi
inocul
infecti
pfspz
challeng
week
last
pfspz
vaccin
serum
prepar
whole
blood
collect
vacutain
tube
bd
contain
clot
activ
kept
room
temperatur
clot
form
tube
centrifug
g
min
serum
fraction
store
peripher
blood
mononuclear
cell
pbmc
isol
whole
blood
ficol
densiti
gradient
centrifug
resuspend
freez
medium
longterm
storag
liquid
nitrogen
cryopreserv
pfspz
thaw
stain
differ
concentr
tanzanian
sera
monoclon
antibodi
sybr
green
thermofish
scientif
min
pfspz
wash
twice
centrifug
g
min
human
serum
antibodi
bind
detect
use
alexa
fluor
goat
antihuman
igg
jackson
immunoresearch
alexa
fluor
goat
antihuman
igm
jackson
immunoresearch
mous
serum
antibodi
bind
detect
use
goat
antimous
igg
biolegend
rat
antimous
igm
bd
bioscienc
fac
diva
version
use
acquisit
sampl
flowjo
version
use
fac
analysi
pfspz
gate
base
high
fluoresc
fitc
channel
median
fluoresc
intens
mfi
pfspz
alexa
fluor
channel
calcul
quantifi
igg
igm
bind
concentr
antibodi
need
achiev
mfi
calcul
interpol
bind
curv
fit
sigmoid
curv
model
graphpad
prism
measur
affin
gate
strategi
found
supplementari
figur
igm
igg
memori
b
cell
isol
frozen
peripher
blood
mononuclear
cell
pbmc
magnet
cell
sort
antibodi
bd
mous
antip
microbead
miltenyi
biotec
follow
fac
sort
use
alexa
fluor
goat
antihuman
igg
jackson
immunoresearch
alexa
fluor
goat
antihuman
igm
invitrogen
pelabel
antihuman
igd
bd
previous
sort
b
cell
immort
epsteinbarr
viru
ebv
plate
singl
cell
cultur
presenc
cpgdna
irradi
pbmcfeeder
cell
two
week
postimmort
cultur
supernat
test
dilut
bind
pfspz
flow
cytometri
use
nowash
protocol
briefli
cryopreserv
pfspz
thaw
stain
supernat
sybr
green
min
room
temperatur
incub
alexa
fluor
goat
antihuman
igg
antihuman
igm
hour
supernat
bind
control
bead
select
exclud
polyreact
antibodi
abil
monoclon
antibodi
serum
prevent
pfspz
invas
travers
vitro
test
previous
briefli
monoclon
antibodi
mix
freshli
dissect
pfgfpluc
sporozoit
dmem
media
contain
fitcdextran
fb
penstrep
fungizon
lglutamin
incub
min
pfspz
ad
hepatoma
cell
plate
one
day
prior
cellswel
plate
final
moi
pfspz
plate
spun
g
min
pfspz
left
infect
min
cell
fix
stain
monoclon
antibodi
conjug
analyz
flow
cytometri
invad
cell
posit
travers
cell
fitcdextran
posit
frg
huhep
mice
purchas
yecuri
inc
infect
bite
pfgfpluc
mosquito
hour
follow
intraperiton
inject
monoclon
antibodi
human
igg
control
describ
parasit
liver
burden
determin
bioluminesc
imag
use
ivi
imag
day
peak
liver
burden
reduct
liver
burden
calcul
normal
mean
control
mice
inject
equival
dose
human
igg
within
bite
experi
anim
procedur
conduct
accord
approv
center
infecti
diseas
research
institut
anim
care
use
committe
iacuc
protocol
seattl
biom
iacuc
adher
nih
offic
laboratori
anim
welfar
standard
olaw
welfar
assur
cdna
synthes
select
bcell
cultur
heavi
chain
light
chain
variabl
region
vh
vl
sequenc
previous
usag
vh
vl
gene
number
somat
mutat
determin
analyz
homolog
vh
vl
sequenc
monoclon
antibodi
known
human
v
j
gene
imgt
databas
version
antibodyencod
sequenc
amplifi
sequenc
primer
specif
v
j
region
given
antibodi
sequenc
align
clustal
omega
version
unmut
common
ancestor
uca
sequenc
vh
vl
infer
antigen
receptor
probabilist
parser
arpp
ua
infer
softwar
previous
construct
use
phylogenet
tree
gener
dna
maximum
likelihood
program
dnaml
phylip
packag
version
antibodi
heavi
light
chain
clone
human
express
vector
express
transient
transfect
cell
thermofish
scientif
use
polyethylenimin
cell
line
routin
test
mycoplasma
contamin
antibodi
affin
purifi
protein
chromatographi
ge
healthcar
kqpadgnpdpnanp
peptid
order
innopep
inc
puriti
contain
chlorin
counter
ion
peptid
ntermin
acetyl
ctermin
amid
elimin
charg
peptid
termini
complex
crystal
solut
contain
mg
tb
buffer
mm
trishcl
mm
nacl
mm
kcl
ph
molar
ratio
peptid
fab
crystal
grown
use
sit
drop
vapor
diffus
well
solut
contain
glycerol
k
typic
appear
within
day
crystal
cryocool
without
addit
cryoprotect
xray
diffract
data
collect
advanc
light
sourc
al
data
collect
process
statist
outlin
supplementari
tabl
data
set
index
integr
scale
use
packag
version
structur
solv
molecular
replac
use
phaser
version
homolog
model
search
model
refin
fab
use
phenixrefin
version
combin
addit
manual
build
cycl
coot
version
posit
fofc
densiti
observ
fab
combin
site
peptid
peptid
manual
built
differ
densiti
fofc
map
follow
addit
round
refin
complex
manual
build
cycl
buri
surfac
area
bsa
calcul
program
ms
version
use
probe
radiu
standard
van
der
waal
total
igg
quantifi
use
halfarea
highbind
plate
corn
goat
antihuman
igg
southernbiotech
use
certifi
refer
materi
sigmaaldrich
standard
test
specif
antibodi
bind
elisa
plate
either
directli
coat
recombin
pfcsp
sequenc
previous
peptid
peptid
first
avidin
sigmaaldrich
follow
nanpnanpnanpnanpna
kqpadgnpdpnanpnvdpn
kqpadgnpdpnanpn
variou
peptid
mutant
nonspecif
bind
plate
coat
irrelev
control
peptid
test
exclud
polyreact
antibodi
peptid
mutant
synthes
biotin
attach
cterminu
lab
plate
block
bovin
serum
albumin
bsa
incub
titrat
antibodi
follow
apconjug
goat
antihuman
igg
southern
biotech
plate
wash
substrat
pnpp
sigma
ad
plate
read
nm
streptavidin
bead
differ
level
fitc
label
spherotech
coat
biotinyl
neg
control
peptid
min
room
temperatur
bead
wash
incub
titrat
monoclon
antibodi
min
room
temperatur
antibodi
bind
detect
alexa
fluor
goat
antihuman
igg
antihuman
igm
uca
compar
bind
concentr
supplementari
fig
biotinyl
peptid
dilut
nm
hepe
buffer
salin
hb
mm
hepe
ph
mm
nacl
mm
edta
surfact
hb
also
use
run
buffer
irrelev
biotinyl
peptid
use
control
nonspecif
interact
neutravidinimmobil
nlc
proteon
sensor
chip
biorad
precondit
nacl
solut
biotinyl
peptid
inject
onto
chip
monoclon
antibodi
dilut
titrat
hb
nm
inject
onto
chip
one
channel
chip
inject
hb
use
refer
analysi
inject
made
flow
rate
inject
time
dissoci
time
respect
bind
interact
monoclon
antibodi
biotinyl
peptid
assess
use
proteon
instrument
biorad
data
process
proteon
manag
softwar
version
ka
kd
kd
calcul
appli
langmuir
fit
model
peptid
acid
length
span
entir
pfcsp
shift
singl
amino
acid
peptid
synthes
coat
onto
microarray
chip
linear
epitop
map
pepperprint
gmbh
peptid
incub
monoclon
antibodi
h
follow
incub
goat
antihuman
igg
detect
antibodi
bind
femal
balbc
mice
week
age
obtain
envigo
laboratori
procedur
perform
accord
guidelin
swiss
feder
veterinari
offic
obtain
ethic
approv
ufficio
veterinario
cantonal
bellinzona
switzerland
approv
number
keyhol
limpet
haemocyanin
klh
conjug
genscript
reconstitut
water
formul
addavax
invivogen
accord
manufactur
instruct
mice
immun
subcutan
peptid
day
mice
bled
day
recov
sera
use
stain
pfspz
flow
cytometri
bind
pfcsp
pfcsp
peptid
elisa
number
mutat
heavi
chain
igg
antibodi
igm
antibodi
isol
tanzanian
volunt
compar
twosid
ttest
result
shown
mean
sd
test
n
refer
number
antibodi
p
df
twotail
spearman
correl
perform
correl
invas
bind
affin
pfspz
repres
experi
p
vivo
test
monoclon
antibodi
error
bar
show
sd
calcul
n
mice
antibodi
onesid
anova
kruskalw
post
test
use
compar
percentag
liver
burden
control
mice
inject
irrelev
human
igg
anova
p
f
kruskalw
post
test
result
individu
antibodi
present
p
twotail
spearman
correl
perform
correl
affin
pfcsp
pfspz
vivo
antibodi
efficaci
repres
experi
p
respect
confid
interv
determin
prism
n
correl
case
n
refer
number
independ
experi
sequenc
data
monoclon
antibodi
isol
studi
deposit
genbank
http
wwwncbinlmnihgovgenbank
xray
structur
factor
coordin
deposit
protein
data
bank
pdb
id
